Accelerating Oncology Peer-to-Peer Scheduling with Klivira

Klivira automates oncology peer-to-peer scheduling, accelerating access to critical cancer treatments by streamlining post-denial reviews for high-cost biologics, advanced imaging, and radiation therapy.

In oncology, PA denials for complex regimens, advanced diagnostics, or off-label indications frequently necessitate peer-to-peer (P2P) reviews. Manually coordinating these calls between busy oncologists and payer medical directors introduces significant delays, impacting time-to-treatment and increasing administrative burden for revenue cycle directors and prior authorization coordinators.

The Unique Challenges of Oncology P2P Reviews

Oncology prior authorization is among the most complex, characterized by high-cost biologics and immuno-oncology agents, frequent regimen changes, and the urgency of cancer treatment. Denials for J-code chemotherapy, advanced imaging like PET/CT, or radiation oncology procedures often hinge on clinical necessity, making peer-to-peer discussions critical. The rapid cadence of PA events—often 10-20 per patient over a treatment course—exacerbates the impact of manual P2P scheduling bottlenecks.

Manual P2P Scheduling: A Bottleneck in Cancer Care

Without automation, the process of scheduling an oncology peer-to-peer review is labor-intensive: PA coordinators must reconcile payer medical director availability with an oncologist's often-packed clinical schedule. This three-way coordination frequently leads to missed P2P windows, delays in securing treatment, and significant clinician burnout, as cited in AMA surveys (src: ama-pa-survey). The manual assembly of detailed clinical documentation, including NCCN Clinical Practice Guidelines and NCCN Drugs & Biologics Compendium citations, further adds to the administrative overhead.

Klivira's Automated Approach to Oncology P2P Scheduling

Klivira's prior authorization automation platform addresses these challenges by integrating peer-to-peer scheduling directly into the denial management workflow. Our system auto-detects P2P-eligible denials for oncology cases, such as those involving off-label use without compendium support or step therapy challenges, and initiates the scheduling process. By integrating with clinician calendars via FHIR Appointment resources (src: fhir-appointment) and ingesting payer availability, Klivira proposes optimal, mutually-available windows, significantly reducing scheduling friction.

Pre-Call Documentation and Outcome Capture for Oncology

For oncology P2P calls, comprehensive documentation is paramount. Klivira automates the assembly of a structured pre-call packet, pulling critical clinical notes, pathology reports (including AJCC TNM staging, molecular markers like ER/PR/HER2, EGFR/ALK/PD-L1, BRCA, MSI/MMR), prior-line treatment history, and relevant compendium citations. Post-call, Klivira facilitates structured outcome capture via a clinician-facing form, writing back critical details into the EMR as FHIR DocumentReference and Communication resources, and triggering subsequent approval or appeal workflows.

Impact on Oncology Workflow and Patient Outcomes

Automating oncology peer-to-peer scheduling directly impacts crucial metrics for cancer care. By reducing the time spent on administrative tasks and accelerating P2P call scheduling, Klivira helps clinics improve time-to-treatment intervals, especially critical for aggressive cancers. Furthermore, by providing pattern analytics on P2P success rates by denial reason and payer, Klivira helps inform upstream PA submission improvements, reducing the likelihood of future denials and enhancing overall PA accuracy for complex oncology regimens.

Frequently asked questions

How does Klivira prioritize urgent oncology peer-to-peer requests?

Klivira's denial-router identifies P2P-eligible denials and, based on configured urgency parameters for oncology cases, prioritizes scheduling. By integrating with both payer availability and clinician calendars via FHIR Appointment resources (src: fhir-appointment), the system proposes the earliest mutually-available window to expedite critical reviews, especially for time-sensitive cancer treatments.

What specific oncology documentation does Klivira automate for P2P calls?

Klivira automates the assembly of a pre-call packet including pathology reports with histology, tumor staging (AJCC TNM), molecular markers (e.g., ER/PR/HER2, EGFR/ALK/PD-L1), prior-line treatment response, ECOG/Karnofsky performance status, and NCCN Drugs & Biologics Compendium (src: nccn-compendium) citations for off-label use. This ensures oncologists have all necessary context for the review.

Can Klivira integrate with my EMR's calendar for oncology clinicians?

Yes, Klivira integrates with ordering clinician calendars via FHIR Appointment resource (src: fhir-appointment) where supported by your EMR, or through customer-configured integrations with common calendar systems like Outlook or Google Calendar. This allows for automated discovery of oncologist availability for peer-to-peer reviews.

How does Klivira handle P2P outcomes for oncology cases?

Post-call, Klivira captures the P2P outcome via a structured clinician-facing form. This outcome, whether an approval, modification, or upheld denial, is then routed into your EMR as FHIR DocumentReference and Communication writes, and triggers appropriate downstream workflows, such as approval write-back or appeal escalation.

Does Klivira provide analytics on oncology P2P success rates?

Yes, Klivira surfaces P2P pattern analytics, including success rates by denial reason, specific payer, and ordering clinician. This data helps revenue cycle teams identify common denial patterns in oncology and refine upstream prior authorization submission strategies to improve initial approval rates and reduce the need for P2P reviews.